Clinical Trials Sponsored by Institut de Recherches Internationales Servier

Total 1814 results

Institut de Recherches Internationales Servier

Not yet recruiting

Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas

Metastatic Adenocarcinoma of the Pancreas

Japan
Institut de Recherches Internationales Servier

Active, not recruiting

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

Glioma

United States
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Glioma

United States
Servier
Institut de Recherches Internationales Servier

Terminated

An Experimental Medicine Clinical Study to Compare Peripheral Immune System From Subjects Without Cancer Diagnosis and Patients With Solid Tumours. (IMMUNOPBMC)

Immune System

France
Institut de Recherches Internationales Servier

Active, not recruiting

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Recurrent Glioma | Grade 2 Glioma | Residual Glioma

United States, Canada, Spain, Italy, United Kingdom, Switzerland, Israel, Japan, Netherlands, Germany, France
Institut de Recherches Internationales Servier

Completed

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy)

Metastatic Cholangiocarcinoma | Advanced Cholangiocarcinoma

United States, Spain, Korea, Republic of, Italy, France, United Kingdom
Institut de Recherches Internationales Servier

Withdrawn

Clinical Investigation to Determine the Accuracy and Benefit of Cardioskin™ in Patients With Known Atrial Fibrillation

Atrial Fibrillation

Netherlands
Institut de Recherches Internationales Servier

Completed

Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

Solid Tumors

Italy, France, Spain
Institut de Recherches Internationales Servier

Completed

Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder

Obsessive Compulsive Disorder

Israel
Institut de Recherches Internationales Servier

Completed

Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms

Alzheimer's Disease

Brazil, South Africa, Chile, Hungary, Bulgaria, Czechia, Germany, Japan, Mexico, Poland, Russian Federation, Slovakia
Institut de Recherches Internationales Servier

Completed

Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris (ASSOCIATE)

Angina Pectoris

Canada
Institut de Recherches Internationales Servier

Completed

Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension

Hypertension

China
Institut de Recherches Internationales Servier

Completed

Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure (SIGNIFY)

Coronary Artery Disease

United Kingdom, Italy
Institut de Recherches Internationales Servier

Terminated

Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) (EYEGUARD-X)

Chronic Uveitis

Italy, United Kingdom, Korea, Republic of, Portugal, Taiwan, Australia, Turkey, Tunisia, Austria, France, Germany, Greece, Spain
Institut de Recherches Internationales Servier

Completed

S90652 in Paediatric Hypertension

Hypertension

France
Institut de Recherches Internationales Servier

Terminated

Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients

Mild Cognitive Impairment

France
Institut de Recherches Internationales Servier

Completed

Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure

Heart Failure, Congestive

Italy
Institut de Recherches Internationales Servier

Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic Syndromes | Relapsed or Refractory Acute Myeloid Leukemia (AML) | Untreated AML | Other IDH1-mutated Positive Hematologic Malignancies

United States, France
Institut de Recherches Internationales Servier

Terminated

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Lymphoma | Advanced Solid Tumors

United States, Spain, France
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)

Leukemia, Myeloid, Acute | Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS)

Spain, United States, France, Korea, Republic of, Taiwan, Australia, Canada, Germany, China, Italy, Austria, Czechia, Poland, Japan, United Kingdom, Russian Federation, Netherlands, Brazil, Israel, Mexico
Institut de Recherches Internationales Servier

Completed

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Glioma | Cholangiocarcinoma | Chondrosarcoma | Other Advanced Solid Tumors

United States, France
Institut de Recherches Internationales Servier

Completed

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

Hepatic Impairment

United States
Institut de Recherches Internationales Servier

Terminated

Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B) (EYEGUARD™-B)

Behcet's Uveitis

Korea, Republic of, United Kingdom
Institut de Recherches Internationales Servier

Completed

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study (SHIFT)

Chronic Heart Failure

France, Sweden
Institut de Recherches Internationales Servier

Completed

The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction

Coronary Disease | Ventricular Dysfunction, Left

United Kingdom
Institut de Recherches Internationales Servier

Completed

S90652 in Paediatric Hypertension

Hypertension

France
Institut de Recherches Internationales Servier
Breast International Group

Completed

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer (FINESSE)

Breast Cancer

United Kingdom, Italy, France, Belgium, Australia, Canada, Germany, Hungary, Spain
Institut de Recherches Internationales Servier
Celgene Corporation

Active, not recruiting

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS) | AML Arising From Antecedent Hematologic Disorder (AHD) | AML Arising After Exposure to Genotoxic Injury

United States, Germany, Netherlands
Institut de Recherches Internationales Servier
ADIR Association

Completed

Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment

Major Depressive Disorder

Bulgaria, Czechia, Finland, Hungary, Russian Federation, Slovakia, Ukraine
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Not yet recruiting

S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene

MTAP-deleted Solid Tumors
Galapagos NV
Institut de Recherches Internationales Servier

Completed

A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis (Roccella)

Osteoarthritis

United States
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Recruiting

A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects

Healthy Subjects

United States
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Recruiting

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

IDH1-mutant Cholangiocarcinoma

United States, United Kingdom
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Recruiting

A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors

Solid Tumor

Spain, Australia, Belgium, United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Recruiting

Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours

Advanced Solid Tumor

Netherlands
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Terminated

Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR)

Metastatic Colorectal Cancer

Denmark, Japan, Belgium, Finland, Hungary, United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.

Acute Myeloid Leukaemia

France, United States, Australia
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

United States, Australia, France, Spain
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Austria, France, Hungary, United Kingdom, Italy, Germany, Spain
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Active, not recruiting

S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

Solid Tumor

United States, Canada
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Active, not recruiting

A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19

Advanced Lymphoid Leukemia

United States, United Kingdom, Japan, France, Spain
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Terminated

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

Autism Spectrum Disorder (ASD)

Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Withdrawn

S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

Esophageal Squamous Cell Carcinoma
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Terminated

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder

Autism Spectrum Disorder (ASD)

Spain, Hungary, Poland, Brazil, France, Italy, Portugal, United Kingdom, Germany, Netherlands
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL)

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

United States, France, Spain, United Kingdom
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1)

Metastatic Colorectal Cancer

United Kingdom, Spain, Germany, Poland, Australia, Belgium, Brazil, Denmark, France, Italy, Netherlands, Russian Federation
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia (CALM)

B-cell Acute Lymphoblastic Leukemia

United States, United Kingdom, Japan, France
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Post Marketing Surveillance Study for ONIVYDE® in South Korea

Metastatic Pancreatic Cancer

Korea, Republic of
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event

Post Stroke Recovery

Belgium, Italy, United Kingdom, Korea, Republic of, Czechia, Poland, Brazil, Australia, Hungary, Canada, France, Germany, Netherlands, Spain, Sweden

Clinical Trials Sponsored by Institut de Recherches Internationales Servier

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations